On December 6, 2022, HCW Biologics Inc. was granted U.S. Patent No. 11,518,792 by the United States Patent and Trademark Office which contains claims for construction of novel multi-function fusion immunotherapeutic compounds comprised of a multi-chain chimeric polypeptide where the first target-binding domain and the second target-binding domain is a soluble human transforming growth factor-β ("TGF-β") receptor (Press release, HCW Biologics, DEC 6, 2022, View Source [SID1234624894]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

This patent provides intellectual property protection for the Company’s lead drug candidate, HCW9218, a heterodimeric, bifunctional fusion protein complex comprising extracellular domains of human tissue factor as a scaffold with target binding domains of TGF-β receptor II, as a TGF-β trap for TGF-β neutralization, and a human interleukin ("IL")-15/IL-15 receptor α complex for immune cell stimulation.